When targeting cancer cells, nanodrugs generally aim to induce immunogenic cell death, triggering the release of tumor antigens and danger-associated molecular patterns, such as calreticulin translocation, high mobility group box 1 protein, and adenosine triphosphate, capable of inducing immune responses to eliminate tumor cells (Kepp et al., 2021; Fu et al., 2022). The gene discussed is CALR; the disease is neoplasm.